Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb 21, 2019--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.
A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.
About Millendo Therapeutics, Inc. Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005135/en/
CONTACT: Millendo Investor Contact:
Stern Investor Relations
email@example.comMillendo Media Contact:
KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Millendo Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 02/21/2019 08:00 AM/DISC: 02/21/2019 08:01 AM